Rose Pitt
Psychiatry · Tustin, CANPI 1841397700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 29.1% of the total. Reporting peaked in 2022 at $1,284 and has fallen 86.5% since, to $174 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bausch Health US, LLC$1K
- Neurocrine Biosciences, Inc.$293
- Ironshore Pharmaceuticals Inc.$284
- Corium, LLC$228
- Otsuka America Pharmaceutical, Inc.$219
- plus $826 from 14 others
What the payments were for
- Food & beverage$4,404100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $1,281 |
| Bausch Health US, LLC | 95 | $1,272 |
| Neurocrine Biosciences, Inc. | 11 | $293 |
| Ironshore Pharmaceuticals Inc. | 15 | $284 |
| Corium, LLC | 12 | $228 |
| Otsuka America Pharmaceutical, Inc. | 10 | $219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $152 |
| Sunovion Pharmaceuticals Inc. | 6 | $85 |
| Lundbeck LLC | 4 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Brainsway USA Inc | 1 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Eisai Inc. | 2 | $32 |
| Tris Pharma Inc | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,404 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 21 | $17,380 |
| Lurasidone Hcl | 25 | $2,281 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 11 | $2,263 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $1,784 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $1,230 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $1,204 |
| Clonazepam | 46 | $941 |
| Bupropion XlBupropion Hcl | 28 | $797 |
| Lamotrigine | 35 | $670 |
| Escitalopram Oxalate | 21 | $338 |
| Alprazolam | 46 | $201 |
| Gabapentin | 16 | $188 |
| Sertraline Hcl | 14 | $154 |
| Lorazepam | 23 | $135 |
| Zolpidem Tartrate | 23 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $152 | $17,38021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Tustin
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.